Abbvie
AbbVie Inc., a global biopharmaceutical leader headquartered in the United States, was established in 2013 as a spin-off from Abbott Laboratories. With a strong presence in North America, Europe, and Asia, AbbVie focuses on developing advanced therapies in immunology, oncology, neuroscience, and virology. The company is renowned for its flagship product, Humira, which has transformed the treatment landscape for autoimmune diseases. AbbVie’s commitment to innovation is evident in its robust pipeline of biologics and small molecules, addressing unmet medical needs. Recognised for its significant contributions to healthcare, AbbVie consistently ranks among the top biopharmaceutical companies worldwide, driven by a mission to improve patient outcomes through science and research.
DitchCarbon Score
How does Abbvie's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Abbvie's score of 52 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Abbvie's reported carbon emissions
In 2024, AbbVie reported total carbon emissions of approximately 300,072,000 kg CO2e for Scope 1 and 122,287,000 kg CO2e for Scope 2. This represents a decrease from 2023, where emissions were about 328,259,000 kg CO2e for Scope 1 and 131,232,000 kg CO2e for Scope 2. The company has set ambitious targets to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using 2021 as the baseline year. Additionally, AbbVie aims to increase its sourcing of renewable electricity from 29.5% in 2021 to 100% by 2030. AbbVie has also committed to reducing its absolute carbon emissions by 25% by 2025, compared to a 2015 baseline. This commitment includes both Scope 1 and Scope 2 emissions. The company is on track to meet its near-term targets, with a long-term goal of achieving net-zero emissions by 2050. These initiatives reflect AbbVie's dedication to sustainability and its proactive approach to addressing climate change within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 402,448,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 418,473,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Abbvie is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
